Insurance coverage for healthcare IT software, to protect healthcare IT companies from damages inflicted by their software

Ah. well they should be protected, with the number of physicians unhappy with the Healthcare IT systems rising. We ll thank goodness patients will also get third party coverage if the software errs.

Chubb Group of Insurance Companies has established the “Healthcare Information Technology” liability insurance to protect Healthcare IT companies.

Over 1,000 companies supply information technology products and services to the healthcare and medical research industries in the US and Canada would be happy to hear that

An integrated liability solution from Chubb can help protect healthcare information technology companies from:

  • general and products liability when software or hardware that is defective or contains inaccurate or incomplete information causes or contributes to patient injuries;
  • errors and omission liability when a product defect or service deficiency results in economic injury to a customer;
  • third-party liability to patients, healthcare providers and others associated with database security breaches; and
  • costs incurred to comply with state, federal

Chubb is targeting Healthcare Information Technology Companies providing any of the following services

  • Electronic health record system providers
  • Clinical decision support system providers
  • Telehealth and health information exchanges
  • Practice management system providers
  • Payor system providers
  • Drug discovery firms
  • Clinical informatics firms
  • Healthcare systems consulting firms

 

Advertisements

Oracle starts the Oracle Health Sciences Institute (OHSI), in partnership with Sun Labs

The Institute is focused on research that will accelerate IT innovation to advance personalized medicine and the delivery of safe and effective   treatments and health care services to patients around the globe. OHSI will work in tandem with academic research centers, focusing on a targeted set of research areas fundamental to the R&D and health care delivery challenges facing health sciences organizations today. Research priorities currently include: artificial intelligence and semantic technology; genomic, genetic and phenotypic data analysis; data mining to support optimization of clinical trials; and predictive algorithms and other technology to advance patient safety and provide advanced decision support at the point of care.Academic institutions interested in collaborating with OHSI in these focus areas should contact OHSI representatives at Oracle http://linkd.in/bXf98c
Oracle starts Oracle Health Sciences Institute (OHSI), in partnership with Sun Labs. This is exiting news and I hope we get to see the participation of Open Source Drug Development Network (OSDD) and initiative by CSIR India earlier supported by Sun Microsystems

22 Million Australian Cloud computing initiative to benefit life science researchers

The Australian Research Collaboration Service (ARCS) www.arcs.org.au has launched its Computer Cloud scheme, a $22 million project funded by the government’s National Collaborative Research Infrastructure Strategy.

More details check http://www.arcs.org.au/index.php/services/cloud-computing

Bob Correll, the chief information officer for the Department of Immigration and Citizenship, said his agency is also looking into using cloud computing for its electronic visa system

FDA Webinar Drug Marketing and Advertising Are You Prepared for the Challenges of Social Media?

Since the FDA cracked down on social media marketing and online advertising, drugmakers have been walking on eggshells. A key FDA meeting is scheduled for Nov. 12-13. Read on …

Drug Marketing and Advertising
Are You Prepared for the Challenges of Social Media?

An FDAnews Webinar
Thursday, Nov. 19, 2009 • 11:00 a.m. — 12:30 p.m. EST

Register Today!

Internet marketing and social media offer powerful new tools to communicate the benefits of your drugs and biologics. But with the FDA a threatening question mark, it’s hard to know how to move forward.

What are the best practices firms can employ while the FDA determines its approach to regulating social media and internet advertising?

Consult the experts.

Dr. Mark DeWyngaert is a leading consultant in drug sales and marketing; he helps drug and biologic makers thread through the FDA maze. Alan Bennett is managing partner in the Washington, D.C. office of Ropes & Gray and has represented clients at the FDA and in Congress on many of the critical issues that affect the pharmaceutical industry. We’ve invited them to spend 90 minutes with you, explaining what the FDA is doing, where it’s heading, and how you can meet your marketing goals — without crossing regulatory boundaries.

In 90 fast-paced minutes, without ever leaving the convenience of your office, you’ll have the opportunity to pick our experts brains — at a cost that’s a fraction of what you’d pay for an on-site consulting visit. They’ll fill you in on key points from the November public meeting and help you prepare for whatever new FDA strategies emerge. Here’s just a taste of this webinar’s agenda:

  • The 5 issues DDMAC is citing in enforcement letters
  • How current regulations and guidance apply to your particular situation
  • The 3 main types of social media: user-generated content, bookmarking and sharing, and social networking
  • What YouTube, Wikipedia, Facebook, Linked-in and Twitter have in common, and how consumers are using them
  • The 6 types of adult online consumers
  • Social media advertising trends
  • How brand reputation is affected by growing product awareness, patient interaction and portability
  • Social media tools — which are high risk, which are low risk
  • Developing an innovative social media monitoring program
  • Using social media monitoring and text mining to create models and identify consumer trends
  • And plenty more!

Because this seminar is web-based and totally interactive, you’ll have plenty of opportunity to email all your questions and receive answers before the session ends.

Advertising and marketing cut across many company departments and functions. Dozens in your company may wish to attend. That’s no problem. As many personnel may log on as you like — for one low registration fee. There are no restrictions except that all registrants must be at the same company location.

The FDA has made no bones about plans to step up enforcement, and DDMAC is at the forefront of agency plans. Now is the time to prepare. Make plans now to log on for this one-time-only session.

Who Will Benefit

  • Compliance officers
  • Sales and marketing professionals
  • Medical affairs personnel
  • General/corporate counsel
  • Regulatory/legislative affairs professionals
  • Communications/public relations professionals

Register now!

Meet Your Instructor
Dr. Mark DeWyngaert
is a managing director in the Life Sciences Advisory Practice at Huron Consulting. Trained as a molecular biologist, he specializes in assisting pharmaceutical manufacturers, biotechnology and medical device companies with identifying and mitigating regulatory risks and valuing intellectual property. As a consultant, he leads teams in the assessment of sales and marketing, medical affairs and clinical development activities, and he assists companies in the redesign of business practices to comply with regulations and standards.

Alan Bennett is managing partner in the Washington, D.C. office of Ropes & Gray and formerly served as co-chair of the firm’s Life Sciences Group. He focuses on legal issues surrounding the development and marketing of medical products and has served as outside counsel to many pharmaceutical and medical device firms. Alan’s practice at Ropes & Gray has involved counseling clients, and representing them at the FDA and in Congress, on many of the critical issues that affect the pharmaceutical industry. He is a recognized expert on issues that arise under the Hatch-Waxman Act, as well as on issues involving pharmaceutical marketing, promotion and education.

Webinar Details
Date: Thursday, Nov. 19, 2009
Location: Your office or conference room (no need to travel!)
Time: 11:00 a.m.12:30 p.m. EST
10:00 a.m. 11:30 a.m. CST
9:00 a.m.10:30 a.m. MST
8:00 a.m. 9:30 a.m. PST
4:00 p.m.5:30 p.m. GMT

Price: Webinar PLUS Audio CD and Transcript: $527 — Best Value!
You’ll have access to one log–in and dial–in for the live 90–minute webinar for unlimited participants! You’ll also receive all presentation materials and the opportunity to ask questions by phone and email, PLUS an audio CD and written transcript of the entire session.

Webinar Only: $327
You’ll have access to one log–in and dial–in for the live 90–minute webinar for unlimited participants! You’ll also receive all presentation materials and the opportunity to ask questions by phone and email.

Gather your team for maximum benefit! Your investment is for one site. Interested in registering multiple sites?
Call (888) 838-5578 in the U.S. or +1 (703) 538-7600 globally
to learn about our special multisite discount.

Register Today!
Please mention priority code 09N06 when registering.

  1. Enroll online.
  2. Call +1 (703) 538-7600 or toll free (888) 838-5578.
    Use your American Express, Visa or MasterCard.
  3. Mail your check to: FDAnews, 300 N. Washington St., Suite 200
    Falls Church, VA 22046-3431

Can’t Attend?
Choose between the Audio CD and transcript or listening in on the Encore presentation:

  • Audio CD and Transcript Only: $327 (plus shipping and handling)
    You’ll receive an audio CD, written transcript of the entire 90-minute audioconference, including the Q&A period, and all presentation materials four weeks after the session.

  • 24/7 ENCORE™ Audio Presentation: $327
    You’ll have access to one dial-in for an archived recording of the entire 90-minute audioconference, including the Q&A period, for unlimited participants. You can dial in any time of day or night for three weeks, from Nov. 23 – Dec. 11, 2009. You’ll also receive all presentation materials.

FDAnews offers a variety of webinars and audioconferences to keep you and your staff current on today’s most important regulatory, legislative and business issues. Click here to view a complete list of the topics available and register today.

Interested in Becoming a Speaker?
We’re always looking for industry leaders eager to share their expertise at an FDAnews audioconference, webinar or physical conference. Our seasoned speaker community includes executives in the pharmaceutical, medical device and clinical trial industries, regulatory affairs, quality control, compliance, healthcare and academia, as well as several former — and current — top FDA officials. Click here to complete our speaker opportunity form and have a representative contact you about future opportunities.

Blogging and complying with FDA and other medical device regulations

Blogging and complying with FDA and other medical device regulations – how to safely generate a corporate blog for a medical device company?

Given that marketing communications for medical device companies are tightly regulated, I wonder how realistic it is for a medical device company to generate a blog. Would love to hear from anyone that has experience or a perspective.

My answers are on Linkedin

http://www.linkedin.com/answers/marketing-sales/search-marketing/MAR_SRC/466277-10937?browseIdx=0&sik=1240994405907&goback=.ama

Succeeding at open-source innovation: An interview with Mozilla’s Mitchell Baker and the USD $34 million Indian Government plan for Opensource Drug Development

Benjamin Franklin said “As we enjoy great advantages from the inventions of others we should be glad of an opportunity to serve others by any invention of ours; and this we should do freely and generously.” – Any one listening !

Leaders and veterans in Biotechnology and Health care research industry may not be welcoming open source ideals. But IT industry has set new benchmarks and proved that open source brings in much needed new ideas and innovation. So hear out loud from none other than chairman and former CEO of Mozilla. The article is published for free at the Mckinsey quarterly

Mitchell comments that Mozilla’s real contribution isn’t just the browser but the model of participation.

In 2005 annual report on Association of American Medical Colleges acknowledged that industry, academic and government researchers can and must work together to remove scientific hurdles in drug development.

For hte uninitaited a look at the article published in Nature Magazine in 2006 with help from Pharma major Eli Lilly-Open source R&D and collaborative drug discovery and other related blogs  MnDoci FuturePundit

And don’t think these are just rants of an overenthusiastic researchers, who doesn’t know the dynamics of business, why because Director-General of the Council for Scientific and Industrial Research (CSIR) in, India unveiled a USD $34 million plan for Open Source Drug Discovery. CSIR is one of the world’s largest publicly funded R&D organisations 38 laboratories working on a range of subjects from molecular biology to road research to Himalayan bio-resources. The Council has more than 4,000 scientists working for it at these 38 labs.

The January 18 2008 meeting in NewDelhi in India was organized by Knowledge Commons, Delhi Science Forum, IIT Delhi, Red Hat and Sun on Free and Open Source model of knowledge. The highlight of the event was opensource drug development — make sure you read the Opensource India blog by Venkatesh

CSIR’s chief Sameer K. Brahmachari says, he looks for “taare zameen par” (stars on earth, a reference to one of Bollywood’s latest blockbusters), in large numbers

OSDD has the support of Sun Microsystems Inc. Hewlett-Packard, IIT Delhi, Red Hat and Indian corporate houses like TCG Life Sciences.

Related Topics Video: open source drug discovery for neglected diseases from google tech talks , Articles: The Ecconomist -An open-source shot in the arm


If you still think open source has no place in biotechnology and life science its not likely that you would listen to Alexander Graham Bell

Great discoveries and improvements invariably involve the cooperation of many minds. I may be given credit for having blazed the trail, but when I look at the subsequent developments I feel the credit is due to others rather than myself.’

George Bush Sings Glory to Open Source

The truth behind the new bill signed into law by President Bush on 26 December 2007, which states that the findings of NIH-funded research must be made freely available to the public within one year of publication.

But all is not Hunky dory , as more obvious once you go through the complete text of the LAW as published in Government website

And it clearly states that copyright law takes precedence over deposition into PubMed Central.

What does that mean, when you publish a research paper it usually belongs to the University or the institution that funded the project. ie if you did sign a copyright transfer agreement with your publisher or sponsor of your funding he can deny the article being published in open source website or journal.

The only surprise is that in future based on the new Law the Director of NIH can prevent publication by grant recipients in journals that don’t allow publications of articles into PubMed Central. Aha now thats not good news for scientists and many are not going to welcome it either

But how many would care NIH is not the lone sponsor of grants, and yes certainly none from healthcare/pharma companies would allow their articles be published at open source journals. that questions how helpful the law would become

But certainly Many Many thanks and Happy New Year to  SPARC and the Alliance for Taxpayer Access  for making the first step, and it sure is a big one

There is certainly going to evoke multiple responses from everyone, wired magazine says its bad news for the science publishing industry, who’ve rallied against initiatives such as PRISM, and other open source websites such as PLOS, to preserve the right of journal publishers to charge for access to federally-funded findings. that means they will find their ways

Am certainly one of those not so politically obsessed persons, and I dont know that many politically savvy lab rats. may be few of those working in stem cell research, cloning or any other controversial topics might be. but I am beginning to like Dubya more. Not a bad a move for someone more associated bad grammar

%d bloggers like this: